

# PHASE I I SCHEDULE

Week I	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00	
14-Mar-22	PA1.1, PA1.2 ( L) (SGD)	Clinical Postings				PA2.1, PA2.6( L )	PH1.3 (SGD)		
15-Mar-22	PH1.1 (L)					MI 1.1 (L),(SGD)	MI 1.2(DOAP)		
16-Mar-22	MI 1.4 (L)					PA2.2, PA2.3( L )	PA2.8( DOAP)		
17-Mar-22	IM4.1 IM4.2, IM4.4 (L)					PH1.2 (L)	CM 7.1, 7.5 (SGD)	MI 1.4(L)	
18-Mar-22	PH1.4 (L)						FM 1.1 & FM 1.3 (L)	PH1.4 (L)	
19-Mar-22	SU7.1(L)	PA2.4 ( L)	PH1.4 (L)	AETCOM 2.1 (SGD)		PA 2.5 (SGD)	CM 7.5, 7.8 ( SGD)	OG1.1 ( L )	
Week II	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00	
21-Mar-22	PA 2.5 (SGD)	Clinical Postings				P A3.1(L)	PH1.4-SGD		
22-Mar-22	PH1.5(L)					MI 1.4, MI 1.5 (SGD)	MI 1.5		
23-Mar-22	MI 1.1(L)					P A3.2(SGD)	PA2.8( DOAP)		
24-Mar-22	IM4.3 IM4.5 (L)					PH1.5(L)	CM 7.5,7.8 (SGD)	MI 1.1(SDL)	
25-Mar-22	PH1.6(L)						FM 1.4 -1.7 ( L)	PH 1.8(L)	
26-Mar-22	AETCOM 2.1 (SGD)	PA1.3 ( SDL)	PA 11.3 (SDL)	PA 2.7 (SDL)		AETCOM 2.1 (SGD)	Pandemic module 2.1	Pandemic module 2.1	

Week III	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
28-Mar-22	PA4.1 (L)	Clinical Postings				PA4.1 (L)	PH1.4-SGD & PH1.5-SGD	
29-Mar-22	PH1.9(L)					MI 1.1 (L)	MI 1.1 & MI 1.2( DOAP)	
30-Mar-22	MI8.9(SGD)					PA 4.3(L)	PA4.1, PA4.2 (SGD)	
31-Mar-22	IM4.8 (L)					PH1.10(L)	CM 7.5,7.8 (SGD)	MI 1.1(SGD)
1-Apr-22	PH1.13(L)						FM 1.9 ( SGD)	PH1.13(L)
2-Apr-22	SU5.1 (L)					PA 5.1 ( L)	PH1.14(L)	AETCOM 2.1 (Skills Lab)
Week IV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		L u n c h	1.00-2.00	2.00-3.00
4-Apr-22	PA 6.1, PA 6.2 (SGD)	Clinical Postings			PA 6.3 ( SGD)		PH1.5-SGD	
5-Apr-22	PH1.14(L)				MI 1.1 (SGD)		MI 1.2(DOAP)	
6-Apr-22	MI 1.1(L)				PA 6.4 ( L)		PA 4.4 ( DOAP)	
7-Apr-22	IM4.9 IM4.10 (L)				PH1.15(L)		CM 7.3 ( L)	MI 3.1 (SGD)
8-Apr-22	PH1.16(L)						FM 2.1 -2.5 (L)	PH1.16(L)
9-Apr-22	SU1.1 ( L)				PA 6.4 (SGD)		PH1.16(L)	AETCOM 2.1 (SGD)
Week V	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
11-Apr-22	PA 6.5, PA 6.6 , PA 6.7( SGD)	Clinical Postings				PA.7.1 ( L)	PH1.7 -SGD(P) & PH1.8-SGD(P)	
12-Apr-22	PH1.16(L)					MI 1.1(L)	MI 1.1 (DOAP) MI 8.9(SGD)	
13-Apr-22	MI 1.1 (L)					PA.7.1 ( L)	PA 5.1 ( SGD + DOAP)	

14-Apr-22	IM1.1, IM1.5				n	PH1.16(L)	CM 7.2 ( L )	MI 1.6 (L) (SGD)
15-Apr-22	PH1.17(L)						FM 2.6 - 2.8 ( L )	PH1.18(L)
16-Apr-22	SU 2.1. 2.2 ( L )	PA.7.2( L )	PH1.18(L)	AETCOM 2.2 ( L )		PA.7.2 ( L )	CM 8.4 ( L )	OG 3.1 ( L )
Week VI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
18-Apr-22	PA.7.3 ( L )	Clinical Postings			L u n c h	PA.7.3 ( SGD )	PH1.8-SGD(P)	
19-Apr-22	PH1.19(L)					MI 1.1(L)	MI 8.10(DOAP) ,MI 1.1(SGD)	
20-Apr-22	MI 1.1 (L)					PA.7.4( SGD )	PA 6.4, PA 6.7( DOAP) PA.7.1 ( DOAP)	
21-Apr-22	IM1.6, IM1.7 (LL)					PH1.19(L)	CM 7.6 ( L )	MI 1.1(L)
22-Apr-22	PH1.19(L)						FM 2.10 (SGD) & FM 2.11 ( L )	PH1.19(L)
23-Apr-22	Pandemic module 2.2					AETCOM 2.2 ( L )	Pandemic module 2.1	Pandemic module 2.1
Week VII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
		Integration week I- Immune responses and Autoimmunity ( PA 9.1 to PA 9.5)				Integration week I- Immune responses and Autoimmunity		
25-Apr-22	Principles and mechanisms in immunity(L) PA 9.1.M1.10	Clinical Postings			L u n c h	Hypersensitivity disorders ( L ) PA 9.2	Hypersensitivity disorders ( SGD) PA 9.2	
26-Apr-22	Immunosuppressants PH 1.50					Hypersensitivity disorders ( L ) PA 9.2	Immunostimulants PH 1.50	
27-Apr-22	Etiopathogenesis of autoimmune disorders and immunodeficiency states MI 1.10 (L)					PA 9.5 SLE ( L )	Newer methods of ELISA,ELFA,CLIA, IFA MI 1.8, 8.15	

28-Apr-22	Rheumatologic Problems IM7.1, IM7.2, IM7.3, IM7.4 (L)				L	Immunosuppressants PH 1.50	CM 5.1 ( L )	Transplant rejections( SGD) PA 9.3			
29-Apr-22	Monoclonal antibodies PH 1.42 , PH 1.43								FM 2.14 (SGD & DOAP )	H 1.43 Cyt otoxic antibiotics	
30-Apr-22	Rheumatologic Problems IM7.5, IM7.6 (L)	Autoimmunity( L) PA 9.4	Calcineurin inhibitors PH 1.50	SLE( SGD) PA 9.5	C	Other AI diseases( SGD) PA 9.7, PA 33.5	CM 5.3( L )	Transplantaton SU 13.1, 13.2 , 13.3 ( L )			
Week VIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00			
2-May-22	PA.7.4 ( SGD )	Clinical Postings			L	PA.7.5 ( SGD )					
3-May-22	PH1.19(L)								MI.1.1(L)	MI1.1 & MI 1.2(DOAP)	
4-May-22	MI 1.7 (L)								PA 8.1. PA 8.2 (SGD)	PA 8.3 (DOAP)	
5-May-22	IIM6.1, IM6.2, IM6.3 (L)								PH1.19(L)	CM 10.5,, 8.3 ( L )	MI 1.8 (L)
6-May-22	PH1.19(L)									FM 2.17 ( SGD & L )	PH1.19(L)
7-May-22	SU1.3 ( L )					PA 9.6 (L)	PH1.24(L)	AETCOM 2.3 ( Seminar)		PA 9.7 (SGD)	CM 8.3 (L)
Week IX	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	L	1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)			
9-May-22	PA.10.1,PA.10.2,PA.10.4 ( SGD)	Clinical Postings			u	PA 11.1 ( SGD )	PH1.12 -SGD(P)				
10-May-22	PH1.24(L)								MI 1.8(L)	MI 1.2(DOAP)	
11-May-22	MI 1.8 (L)(SDL)								PA 11.2 ( SGD )	PA 10.3 ( SGD) PA 10.3 ( DOAP)	
12-May-22	IIM6.4, IM6.5, IM6.7 (L)								PH1.25(L)	CM 5.3 (SGD)	MI 1.8(L)
13-May-22	PH1.25(L)									FM 2.20 (L)	PH1.26(L)

14-May-22	<b>SU 4.1, SU4.2 ( L )</b>	PA 12.1, PA 12.2 ( SGD )	PH1.27(L)	AETCOM 2.3 ( Seminar)		PA 12.3( SGD)	CM 5.3 (SGD)	<b>OG 4.1 ( L )</b>	
Week X	<b>8.30-9.30</b>	<b>9.30-10.30</b>	<b>10.30-11.30</b>	<b>11.30- 12.30</b>	<b>L</b>	<b>1.00-2.00</b>	<b>2.00-3.00</b>	<b>3.00-4.00</b>	
16-May-22	PA13.1,PA13.2 (SDL)	<b>Clinical Postings</b>			<b>u</b>	PA13.3 ( SGD)	PH1.13- SGD		
17-May-22	PH1.27(L)					MI 1.8(L)		MI 1.8 &MI 8.5 (DOAP)	
18-May-22	MI 1.8(L)					PA13.4 (L)	PA13.3 ( SGD)	PA13.3 ( SGD)	
19-May-22	IM9.1, IM9.2 (L)					PH1.28(L)	CM 5.3( L)	MI 1.10 (L)	
20-May-22	PH1.29(L)						FM 2.21&2.22 ( L)	PH1.31(L)	
21-May-22	AETCOM 2.4 ( Vist)	AETCOM 2.4 ( Vist)	AETCOM 2.4 ( Vist)	AETCOM 2.4 ( Vist)		PA14.1 (SDL)	Pandemic module 2.2	Pandemic module 2.2	
Week XI	<b>8.30-9.30</b>	<b>9.30-10.30</b>	<b>10.30-11.30</b>	<b>11.30- 12.30</b>	<b>L</b>	<b>1.00-2.00</b>	<b>2.00-3.00</b>	<b>3.00-4.00</b>	
23-May-22	PA14.2(L)	<b>Clinical Postings</b>			<b>u</b>	PA14.2 (SGD)	PH1.13 - SGD		
24-May-22	PH1.32(L)					MI 1.10		MI 1.2, MI 1.8, MI 8.15(DOAP)	
25-May-22	MI 1.10(L)					PA15.1, PA 15.4		PA13.5 (DOAP)	
26-May-22	IM1.3, IM1.9(L)					PH1.34(L)	CM 5.1 (SGD)	MI 1.11(L)	
27-May-22	PH1.35(L)						FM 2.25 ( L)	PH1.36(L)	
28-May-22	<b>SU12.1, 12.2 , 12.3 ( L )</b>	PA15.1 (L)	c PH1.36(L)	AETCOM 2.4 ( SGD )		PA15.2 ( SGD)	CM 5.2 (SGD)	<b>OG 4.1 ( L )</b>	
Week XII	<b>8.30-9.30</b>	<b>9.30-10.30</b>	<b>10.30-11.30</b>	<b>11.30- 12.30</b>	<b>L</b>	<b>1.00-2.00</b>	<b>2.00-3.00</b>	<b>3.00-4.00</b>	
30-May-22	PA16.1 , PA16.2 ( L )	<b>Clinical Postings</b>			<b>u</b>	PA16.3 ( L)	PH1.20 - SGD & PH1.21 - SGD		
31-May-22	PH1.37(L)					MI 1.9(L)		MI 1.2 MI 8.7(DOAP)	
1-Jun-22	MI8.5 8.6 & 7 (SGD)					PA16.3 ( L)	PA14.3 ( SGD)	PA14.3 ( DOAP)	
2-Jun-22	IM1.3(L)					PH1.38 (L)	CM 5.3 (SGD)	MI 1.1(L)	
3-Jun-22	PH1.38 (L)						FM 2.25&2.26 ( SGD)	PH1.39(L)	
4-Jun-22	<b>SU 15.1 ( L )</b>					PA16.4 ( L)	PH1.40(L)	<b>OG 23.1 ( L )</b>	

Week XIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	1.00-2.00	2.00-3.00	3.00-4.00
		II Integration week- Tuberculosis			II Integration week- Tuberculosis		
6-Jun-22	Common ethiological agents of respiratory tract infections MI.6.3	Clinical Postings			Describe the pathogenesis and pathology of tuberculous lymphadenitis PA 19.2	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	
7-Jun-22	Describe the first line antitubercular drugs, their mechanisms of action, side effects and doses. PH 1.44				Discuss the Laboratory Diagnosis of Tuberculosis MI 6.3	Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) MI 6.3,	
8-Jun-22	Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of pulmonary tuberculosis PA 26.4				Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of pulmonary tuberculosis PA 26.4	Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen PA 19.3	
9-Jun-22	IM 3.1 (L)				Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	CM 8.1 ( L )	Non Tuberculosis mycobacterial disease MI6.3

L  
u  
n  
c  
h

10-Jun-22	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45					FM 2.35 (SGD)	Describe vaccines and their uses PH 1.54	
11-Jun-22	IM 3.2, 3.3 (L)	Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine PA 24.5	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	AETCOM 2.4 (SGD)	L u n c h	Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine PA 24.5	CM 8.1 (L)	OG 5.2 (L)
Week XIV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
13-Jun-22	PA 17.1 (L)	Clinical Postings			L u n c h	PA 17.1, PA 17.2 (SGD)	PH1.22 - SGD & PH1.23 - SGD	
14-Jun-22	PH1.41(L)					MI 8.5, 8.6 (SDL)	MI 8.7 (DOAP)	
15-Jun-22	MI6.1(L)					PA18.1 (SGD)	PA15.3 (SGD)	PA15.3 (DOAP)
16-Jun-22	IM1.3(L)					PH1.42(L)	FM 3.3 -3.5 (L)	MI 8.5, 8.6 (SGD)
17-Jun-22	PH1.43(L)						CM 5.6( L)	PH1.43(L)
18-Jun-22	Pandemic module 2.2	AETCOM 2.4 (SGD)	AETCOM 2.5 (L)	AETCOM 2.5 (SGD)	Pandemic module 2.2	Pandemic module 2.2	Pandemic module 2.2	
Week XV	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)	
20-Jun-22	PA18.2 (L)				L	PA18.2 (L)	PH1.32 - SGD	

21-Jun-22	PH1.43(L)	Clinical Postings			u n c h	MI 2.1, 2.2(L)	MI 2.4, 2.3, 8.15 (SGD)(DOAP)	
22-Jun-22	MI 8.1(SGD)					PA18.2 ( L )	PA16.6( DOAP)	PA16.7( DOAP)
23-Jun-22	IM2.1, IM2.2, IM2.3, IM2.4 (L)					PH1.44(L)	CM 5.8 (SGD)	micro
24-Jun-22	PH1.45(L)						FM 3.6 -3.8 (L)	PH1.46(L)
25-Jun-22	SU 16.1 ( L )					PA18.2 ( L )	PH1.47(L)	OG 23.2(L)
Week XVI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)
27-Jun-22	PA19.4 (L)	Clinical Postings			L u n c h	PA19.4 (L)	PH1.32 - SGD& PH1.33 -SGD	
28-Jun-22	PH1.47(L)					MI 3.3(L)	MI 3.4, 8.15 (DOAP)	
29-Jun-22	MI 1.1(SDL)					PA19.5 (L)	PA18.1 ( DOAP)	PA18.2 ( DOAP )
30-Jun-22	IM2.5 (L)					PH1.48(L)	CM 8.2 ( L )	MI 1.1 (L)
1-Jul-22	PH1.48(L)						FM 3.9 &3.10 ( L& SGD )	PH1.49(L)
2-Jul-22	SU6.1 ( L )					PA19.6 (SGD)	PH1.49(L)	OG 23.3 (L)
Assessment Week								
4-Jul-22	Pathology					Skill Assessment in Batches		
5-Jul-22	Pharmacology							
6-Jul-22	Microbiology							
7-Jul-22	Forensic Medicine							
8-Jul-22	General Medicine							
9-Jul-22	Community Medicine					Obstetrics and Gynecoogy		
Week XVII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
11-Jul-22	PA20. 1 (SGD)	Clinical Postings			L u n c	PA20. 1 (SGD)	PH1.33 -SGD	
12-Jul-22	PH1.49(L)					MI 2.7(L)	MI 1.1, 2.7, 8.15(SGD)(DOAP)	
13-Jul-22	MI2.7(L)					PA 21.1 (SGD)	PA19.5 (DOAP)	PA19.7 (DOAP)



14-Jul-22	IM2.14, IM2.15, IM2.16 (L)				h	PH1.50(L)	CM 3.1 ( L )	MI1.1 (L)
15-Jul-22	PH1.51(L)						FM 3.11(SGD ,Autopsy)	FM3.11 ( SGD)
16-Jul-22	<b>SU 10.1 , 10.2 ( L )</b>	<b>PA 21.2 (L)</b>	AETCOM 2.5 (SGD)	AETCOM 2.5 (SGD)		PH1.52(L)	CM 3.1 ( L )	Assessment/ Remedial/ Sports
Week XVIII	<b>8.30-9.30</b>	<b>9.30-10.30</b>	<b>10.30-11.30</b>	<b>11.30- 12.30</b>		<b>1.00-2.00</b>	<b>2.00-3.00</b>	<b>3.00-4.00</b>
18-Jul-22	<b>PA 21.2 (L)</b>	Clinical Postings			L u n c h	<b>PA 21.3 ( SGD)</b>	PH1.34 -SGD	
19-Jul-22	PH1.54(L)					MI2.5 MI 1.1 (L)	MI 1.2 (DOAP),MI1.1 (SGD)	
20-Jul-22	MI2.5 (L)					<b>PA 21.4 ( L )</b>	<b>PA 21.1 to 21.5 ( SGD)</b>	<b>PA 21.1 to 21.5 ( SGD)</b>
21-Jul-22	IM9.3, IM9.4, IM9.5, IM9.6, IM9.7, IM9.8 (L)					PH1.55(L)	CM 3.1 ( SGD )	MI 1.1(SGD)
22-Jul-22	PH1.56(L)						FM3.11 (SGD)	FM 3.20
23-Jul-22	AETCOM 2.5 ( SDL)					<b>PA22.1 ( SDL)</b>	<b>PA22.1 ( SDL)</b>	AETCOM 2.5 ( SDL)
Week XIX	<b>8.30-9.30</b>	<b>9.30-10.30</b>	<b>10.30-11.30</b>	<b>11.30- 12.30</b>	L u n c h	<b>1.00-2.00</b>	<b>2.00-3.00</b>	<b>3.00-4.00</b>
25-Jul-22	<b>PA 21.5( SGD)</b>	Clinical Postings			L u n c h	<b>PA22.4, PA 22.7(L)</b>	PH1.34 -SGD	
26-Jul-22	PH1.57(L)					MI 2.5(L)	MI 2.6. 8.15 (DOAP)	
27-Jul-22	MI 1.1 (SGD)					<b>PA22.5 ( SGD)</b>	<b>PA22.2 ( SGD)</b>	<b>PA22.2 ( DOAP)</b>
28-Jul-22	IM4.6 , IM4.7 (L)					PH1.58(L)	CM 3.5 (SGD)	MI 3.1(L)
29-Jul-22	PH1.59(L)						FM 8.1 & 8.2 (L)	FM 8.3 - 8.5 (L)
30-Jul-22	<b>SU3.1 ( L )</b>					<b>PA22.6 ( L)</b>	AETCOM 2.6 ( SGD )	AETCOM 2.6 ( L)

Week XX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
1-Aug-22	PA24.1 ( L)	Clinical Postings			L u n c h	PA24.2 ,24.3, ( L)	PH1.34 -SGD	
2-Aug-22	pharmac PH1.63(L)					MI3.1(L)	ML3.2, 8.15(DOAP)	
3-Aug-22	MI3.6, 3.1(SGD)					PA 24.4 ( L)	PA.24.1 (DOAP)	PA24.2 ,24.3, 24.4( DOAP)
4-Aug-22	OG 8.1 ( L)					PH1.64(L)	CM 8.1 ( SDL)	MI 3.1 (SGD)
5-Aug-22	PH1.64(L)						FM 8.6 -8.8 ( L )	FM 8.9 & FM 8.10 ( L )
6-Aug-22	SU 14.1, 14.2 , 14.3 ( L)					PA24.6( L)	AETCOM 2.6( SGD )	Pandemic module 2.3
Week XXI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
8-Aug-22	PA24.7( L)	Clinical Postings			L u n c h	PA25.1( SGD)	PH2.1 DOAP	
9-Aug-22	PH3.1 skill station					MI4.1, 4.2,4.3(L)	MI3.8, 8.15(DOAP), MI 1.1(SGD)	
10-Aug-22	MI4.3(L)					PA25.3(L )	PA24.5; 24.6;24.7 (DOAP)	PA24.1 to 24.7( SGD)
11-Aug-22	IM5.1, IM5.2 (L)					PH3.1 skill station	CM 8.1 ( SDL)	MI4.1(L)
12-Aug-22	PH3.1 skill station						FM 9.1 (SGD & seminar)	FM 9.1 ( SGD & seminar)
13-Aug-22	SU 9.1 , 9.2 ( L)					PA25.4(L)	AETCOM 2.7( SGD )	AETCOM 2. 7( L)
Week XXII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
15-Aug-22	PA25.2; 25.5(L)	Clinical Postings			L u n	PA 26.1 (L)	PH2.2 DOAP	
16-Aug-22	PH3.1 skill station					MI4.3(L)	MI4.3(SDL),MI 4.1, 4.3, 8.15(DOAP)	
17-Aug-22	MI4.3(L)					PA 26.2, ,26.3 ( L)	PA 25.1-25.7 (SGD)	PA 25.1-25.7 (DOAP)

18-Aug-22	IM5.3, IM5.4 (L)				c h	PH3.1 skill station	CM 8.1 (SDL)	MI4.3(L)
19-Aug-22	PH3.1 skill station						FM 9.1 (SGD & seminar)	FM 9.2 (SGD & seminar)
20-Aug-22	Pandemic module 2.3	AETCOM 2.6(SDL)	AETCOM 2.6(SDL)	Pandemic module 2.3		Pandemic module 2.3	Pandemic module 2.3	
Week XXIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
22-Aug-22	PA 26.5( L)	Clinical Postings			L u n c h	PA 26.6, ,26.7( L)	PH2.3 DOAP	
23-Aug-22	PH3.2 skill lab					MI5.1(L)	MI4.3(SDL),4.3, 8.15(SGD)(DOAP)	
24-Aug-22	MI5.1(L)					PA 26.1 to 26.7 (SGD)	PA 26.1 (DOAP)	PA 26.6, ,26.7( DOAP)
25-Aug-22	IM5.5, IM5.6 (L)					PH3.3 skill lab	CM 8.1 (SDL)	micro
26-Aug-22	PH3.3 skill lab						FM 9.3 (SGD)	FM 9.3 (SGD)
27-Aug-22	SU 11.1, 1.2 ,1.3 ( L)					PA 27.1 ( L)	AETCOM 2.7( SGD)	AETCOM 2.7( L)
Week XXIV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
	III Integration week- Diabetes Mellitus					III Integration week- Diabetes Mellitus		
29-Aug-22	Epidemiology, Etiopathogenesis, (L) PA 32.4, IM 11.2, 11.3, CM 8.2				L u n c h	C/F & complications of DM (L,SGD) IM 11.5, PE 33.4, DR 18.1, OG 12.3	Treatment of Diabetic ketoacidosis (SGD) PH1.36	

30-Aug-22	Insulin (L, SGD)PE 33.4, IM 11.2, IM 11.3- OG 12.3-	Clinical Postings
31-Aug-22	Agents causing wound infections MI4.3	
1-Sep-22	Gross and microscopic changes in organs (SGD) PA28.7-	
2-Sep-22	Insulin Resistance (L, SGD) PE 33.4, IM 11.2, IM 11.3- OG 12.3-	

<b>n c h</b>	Methods of specimen collection and laboratory diagnosis of common infections in Diabetes(L) MI 17.3	Perform and identify the causative agents of infections in Diabetes( DOAP) MI 1.2	
<b>L U N C H</b>	Charts (SGD) PA-28.7	Perform urine tests- sugar and ketone bodies and urinary dipstick tests (SGD, DOAP) PA 32.4, IM 11.11, 11.13, PE 335, PE	
	PH 1.36 Insulin analogue ( L)	Epidemiology, control measures, use of lab tests at primary care level for DM (L,SGD) CM 8.2	Laboratory diagnosis of wond infections MI.4.3
		FM 9.3 (SGD)	FM 9.3 (L)

3-Sep-22	Lab investigations of DM ( SGD, DOAP) PE 33.5, IM 11.11, IM 11.13-	Glomerular manifestati on of DM (L, SGD) PA28.7	Oral antidiabetic drugs ( L ) PH 1.36	Enumerate and evaluate the need for screening tests (SGD, DOAP) CM 7.6		Feed Back	Formative Assessment/ Reflective exercise	Formative Assessment/ Reflective exercise
Week XXV	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	L u n c h	1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)
5-Sep-22	PA 27.5 ( L)	Clinical Postings				PA 27.4( L)	PH2.4 DOAP	
6-Sep-22	PH3.4 skill station					MI5.2(L)	MI4.3(SGD), 5.2, 8.15(DOAP)	
7-Sep-22	MI(5.2) L					PA 27.6( L)	PA 27.1 ( DOAP)	PA 27.8( DOAP)
8-Sep-22	IM 3.1, 3.2, IM3.3 (L)					PH3.4 skill station	CM	MI 5.2(SGD)
9-Sep-22	PH3.4 skill station						FM 9.4 ( SGD)	FM 9.4 (SGD)
10-Sep-22	SU 11.5 ( L )	PA 27.2( SGD)	AETCOM 2.7(SGD)	Pandemic module 2.4		PH3.4 skill station	CM	Assessment/ Remedial/ Sports
Week XXVI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
12-Sep-22	PA 27.3, 27.7( SGD)	Clinical Postings				PA 27.9( SGD)	PH3.1 skill station	
13-Sep-22	PH3.4 skill station					MI6.1(L)	MI 5.2 (DOAP)	
14-Sep-22	MI4.1 ,1.1 (L)					PA 27.1 to 27.9( SGD)	PA 28.2 (SGD)	PA 28.3; 28.4 ( SGD)
15-Sep-22	IM8.1, IM8.2, IM8.3 (L)					PH3.4 skill station	CM	MI 6.1 (SDL)
16-Sep-22	PH3.5 skill station						FM 9.4 (SGD)	FM 9.4 (L)

17-Sep-22	Pandemic module 2.4	PA 28.1 (SDL)	AETCOM 2.7( SDL)	AETCOM 2.7( SDL)	Pandemic module 2.4	Pandemic module 2.4	Pandemic module 2.4
Week XXVII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	1.00-2.00	2.00-3.00	3.00-4.00
19-Sep-22	PA 28. 2, 28.3, 28.4( L)	Clinical Postings			PA 28.5,28.6 ( L)	PH3.1 skill station	
20-Sep-22	PH3.5 skill station				MI6.1(L)	MI 6.2 (DOAP)	
21-Sep-22	MI 6.1(SGD)				PA 28.7 ( SGD)	PA 28,12,13,15 ( SGD)	PA 28.14( DOAP)
22-Sep-22	IM8.4, IM8.5, IM8.6 (L)				PH3.5 skill station	CM 8. 1 ( SGD)	MI 6.1 (SGD)
23-Sep-22	PH3.5 skill station					FM 9.5 ( SGD)	FM 9.5 ( SGD)
24-Sep-22	SU , 8.3 8.1 ( L )				PA28.8,28.9( SGD)	AETCOM 2.8( Visit)	AETCOM 2.8( Visit)
Week XXVIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	1.00-2.00	2.00-3.00	3.00-4.00
		IV Integration Meningitis			IV Integration Meningitis		
26-Sep-22	Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Clinical Postings			Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Treatment of bacterial meningitis	
27-Sep-22	Rational antibiotic use				Etiopathogenesis, clinical course & lab diagnosis of meningitis MI5.2(L)	laboratory diagnosis of agents causing meningitis MI5.3, MI 8.15(DOAP)	

L  
u  
n  
c  
h

L  
u

28-Sep-22	Identify the microbial agents causing meningitis MI5.3	Clinical Postings			n c h	Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Identify the etiology of meningitis based on given CSF parameters PA 35.3	
29-Sep-22	OG 9.1					Treatment of Viral meningitis	CM 8.1 ( L)	Agents of aseptic meningitis MI5.1(L)
30-Sep-22	Treatment of Fungal meningitis						FM 9.5 SGD	FM 9.5 (Autopsy + Lecture)
1-Oct-22	OG 9.5 ( L)	Treatment of TB meningitis	Feed Back	Formative Assessment/ Reflective exercise	Formative Assessment/ Reflective exercise	CM 8.1 ( L)	Formative Assessment/ Reflective exercise	
	<b>FORMATIVE ASSESSMENT</b>					<b>FORMATIVE ASSESSMENT</b>		
3-Oct-22	Pathology					Skill Assessment n Batches		
4-Oct-22	Pharmacology							
5-Oct-22	Microbiology							
6-Oct-22	Forensic Medicine							
7-Oct-22	General Medicine							
8-Oct-22	Community Medicine					General Surgery		
						Obstetrics and Gynecology		
Week XXIX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
10-Oct-22	PA 28.10 ( SGD)	Clinical Postings			L u	PA 28.11 ( SGD)	pharmac PH3.2 skill lab patho/pharmac/micro	
11-Oct-22	pharmac PH3.5 skill station					MI 6.1 ( L ))	MI 6.3 (DOAP)	

12-Oct-22	MI 6.1 (SGD)	Clinical Postings			n c h	PA 28.14, 28.16(L)	patho/pharmac/micro	
13-Oct-22	OG 19.1 ( L )					pharmac PH3.5 skill station	CM 8. 1 ( SGD)	MI 6.1 (SGD)
14-Oct-22	pharmac PH3.5 skill station						FM 9.6 ( SGD)	Assessment/ Remedial/ Sports
15-Oct-22	SU6.2 ( L )	PA 28 1 to PA 28.16 ( SGD)	AETCOM 2.8( LGD)	Pandemic module 2.4		pharmac PH3.5 skill station	Assessment/ Remedial/ Sports	Assessment/ Remedial/ Sports
Week XXX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
17-Oct-22	PA 29.1 ( L )	Clinical Postings			L u n c h	PA 29.2, 29.4 ( L )	pharmac PH3.3 skill lab &PH3.4 skill station patho/pharmac/micro	
18-Oct-22	pharmacPH3.5 skill station					MI 7.3(L)	MI 6.3, 1.2(DOAP)	
19-Oct-22	MI 7.3 (SGD)					PA 29.3, 29.5( SGD)	PA 29.2, 29.3( DOAP)	PA 29.1 to 29.5 (SGD)
20-Oct-22	OG 19.4 ( L )					pharmacPH3.7 skill station	CM 8. 1 ( SGD)	MI7.2(L)
21-Oct-22	pharmac PH3.7 skill station						FM 9.6 ( SGD)	Assessment/ Remedial/ Sports
22-Oct-22	Pandemic module 2.5	AETCOM 2.8( SDL)	AETCOM 2.8( SDL)	Pandemic module 2.5	Pandemic module 2.5	Pandemic module 2.5	Pandemic module 2.5	
Week XXXI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
24-Oct-22	PA 30.1 ( L )	Clinical Postings			L u n	PA 30.2, 30.9 ( L )	pharmac PH3.4 skill station patho/pharmac/micro	
25-Oct-22	pharmac PH3.7 skill station					MI 7.2(SGD)	MI7.3, 7.1, 7.2(DOAP)(SDL)	
26-Oct-22	MI 8.5, MI 6.6(L)					PA 30.3( L )	PA 30.7,PA 30.8( SGD)	PA 30.7,PA 30.8( DOAP)





Week XXXIIV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
14-Nov-22	PA 32.5 ( SGD)	Clinical Postings			L u n c h	PA 32.7( SGD)	PH4.1 DOAP	
15-Nov-22	PH5.1SGD					MI 1.1 (SGD)	MI 8.12 (SGD)AETCOM	
16-Nov-22	MI 8.13 (SGD)					PA 32.1 to 32.9 ( SGD)	PA 31.3( DOAP)	PA 31.1 to 31.4 ( SGD)
17-Nov-22	OG 22.1 ( L )					PH5.1SGD	CM 14.1,14.2 & 14.3 ( L)	MI8.16(L)
18-Nov-22	PH5.1SGD						FM 9.6 ( SGD)	Assessment/ Remedial/ Sports
19-Nov-22								
Week XXXV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
21-Nov-22	PA 33.2 ( L)	Clinical Postings			L u n c h	PA 33.3 ( L)	PH4.2 skill lab	
22-Nov-22	PH5.2 SGD					MI 6.1(L)	MI 8.14(SGD)	
23-Nov-22	micro					PA 33.1,33.4( SGD)	PA 32.1 ( DOAP)	PA 32.2, 32.3 ( DOAP)
24-Nov-22	OG 22.2 ( L )					PH5.2 SGD	CM 13.1,2, 3& 4 ( L)	micro
25-Nov-22	PH5.2 SGD						FM	Assessment/ Remedial/ Sports
26-Nov-22	SU 4.3 ( L )					PA 33.1 to 33.5 ( SGD)	AETCOM	AETCOM
Week XXXVI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
28-Nov-22	PA 34.1, 34.2,34.3( L)	Clinical Postings			L u n c h	PA 34.1, 34.2,34.3( SGD)	PH 5.1SGD	
29-Nov-22	PH5.4SGD					micro	patho/pharmac/micro	
30-Nov-22	micro					PA35..2, 36.1( L)	PA 33.2( DOAP)	PA 34.4, 36.1 ( DOAP)
1-Dec-22	SU 5.4 ( L )					PH5.5 SGD	CM11.1 to CM 11.5 ( L)	micro
2-Dec-22	PH5.6 SGD						FM	Assessment/ Remedial/ Sports

3-Dec-22	SU 7.2 ( L )	PA35..2, 36.1 ( SGD)	AETCOM	AETCOM	PH5.7 SGD	Assessment/ Remedial/ Sports	Assessment/ Remedial/ Sports
	<b>SUMMATIVE ASSESSMENT/ MODEL EXAMNATION</b>					<b>SUMMATIVE ASSESSMENT/ MODEL EXAMNATION</b>	
5-Dec-22	Pathology Paper I						
6-Dec-22	Pathology Paper II						
8-Dec-22	Pharmacooogy Paper I						
9-Dec-22	Pharmacooogy Paper II						
12-Dec-22	Mcrobiology Paper I						
13-Dec-22	Mcrobiology Paper II						
14-Dec-22	Pathology/ Pharmacooogy/ Microbiology				Practicals and Viva		
15-Dec-22							
16-Dec-22							
19-Dec-22							
20-Dec-22							
21-Dec-22							

































